$ATRS at breakout $2.59
off 10 day at upper bollie
Nasdaq GM
Website
10-K 3/15/17
80% x 100% Strong Buy
Last ten trades
Shares Outstanding 155.09M
Float 116.71M
% Held by Insiders 19.71%
% Held by Institutions 35.50%
Shares Short 3 2.52M
Short Ratio 2.7
Short % of Float 1.78%
Shares Short (prior month) 2.83M
Stock technical analysis
News
and filings
Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The companys injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It also offers Elestrin gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; and Gelnique, an oxybutynin gel product for the treatment of overactive bladder. In addition, the company is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes; VIBEX QuickShot (QS) auto injectors for reducing risk of preterm birth; VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency; and Vibex QS M for the treatment of CNS indication. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals Inc. and Ferring B.V.; JCR Pharmaceuticals Co., Ltd.; Teva Pharmaceutical Industries, Ltd.; Actavis plc; Meda Pharmaceuticals, Inc.; and AMAG Pharmaceuticals, Inc. The company was founded in 1979 and is headquartered in Ewing, New Jersey.
off 10 day at upper bollie
Nasdaq GM
Website
10-K 3/15/17
80% x 100% Strong Buy
Last ten trades
Shares Outstanding 155.09M
Float 116.71M
% Held by Insiders 19.71%
% Held by Institutions 35.50%
Shares Short 3 2.52M
Short Ratio 2.7
Short % of Float 1.78%
Shares Short (prior month) 2.83M
Stock technical analysis
News
and filings
Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The companys injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It also offers Elestrin gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; and Gelnique, an oxybutynin gel product for the treatment of overactive bladder. In addition, the company is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes; VIBEX QuickShot (QS) auto injectors for reducing risk of preterm birth; VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency; and Vibex QS M for the treatment of CNS indication. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals Inc. and Ferring B.V.; JCR Pharmaceuticals Co., Ltd.; Teva Pharmaceutical Industries, Ltd.; Actavis plc; Meda Pharmaceuticals, Inc.; and AMAG Pharmaceuticals, Inc. The company was founded in 1979 and is headquartered in Ewing, New Jersey.
